Apr 14, 2026 | Daraxonrasib Nearly Doubles Pancreatic Cancer Survival; Neurocrine-Soleno $2.9B Deal

Daraxonrasib slashes death risk 60% in metastatic pancreaticcancer Phase 3 — Revolution Medicines leads a $1.5B offering wave. Neurocrine acquires Soleno for $2.9B, Regeneron enters radiopharma via Telix, and Travere nabs the first-ever FSGS approval with Filspari.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, daraxonrasib, Revolution Medicines, RVMD, pancreatic cancer, RASolute 302, Neurocrine Biosciences, Soleno Therapeutics, VYKAT XR, Prader-Willi syndrome, Filspari,sparsentan, Travere Therapeutics, FSGS, Regeneron, Telix Pharmaceuticals, radiopharmaceuticals, Eli Lilly, CrossBridge Bio, ADC, antibody-drug conjugate, Jaypirca, pirtobrutinib, CLL, ORIC Pharmaceuticals, rinzimetostat, Zentalis,azenosertib, Allogene, cema-cel, CAR-T, Johnson & Johnson, Icotyde, Spyre Therapeutics, SPY001, ulcerative colitis, Pfizer, Adcetris, Lilly, Roche, AstraZeneca, J&J, Gilead